Page 29 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Brachytherapy versus external beam in local dose escalation

Main results For both modalities, clinically relevant deteriorations were observed on all scales at the end of treatment. However, the scores returned to nearly baseline levels within 6 – 12 months, with the exception of QLQ-H&N35- xerostomia. Comparable outcomes, toxicity (except for acute G≥2 dermatitis), and QoL- scores were achieved with both modalities The HDR group 1 – 2 fr had the best actuarial survival and LC ra

Median FU PDR: 66 months; CK: 36 months - p<0.05)

Late toxicity G≥2 skin: PDR: 2; CK: 1; p=0.868 G≥2 subcutaneous: PDR: 1; CK: 1; p=1.000 G≥2 mucosal: PDR: 10; CK: 8; p=0.430 G≥2 xerostomia: PDR: 12; CK: 16; p=0.286 G≥2 dysphagia: PDR: 8 CK: 11 p=0.347 G≥2 pain: PDR: 3; CK: 6; p=0.141 -

Acute toxicity G≥2 dermatitis: PDR: 15; CK: 29; p=0.006* G≥2 mucositis: PDR: 59; CK: 70; p=0.058 G≥2 dysphagia: PDR: 64; CK: 72; p=0.185 G≥2 pain: PDR 29; CK 40; p=0.068 G≥3 dysphagia: PDR: 20; CK: 17; p=0.474 2D-EBRT: 1.9%; HDR 1 fr: 4.2%; HDR 3 fr: 13.8%

At 3 y p=0.83
OS DFS, PDR: 83%; CK: 81%; -

CSS At 3 y, PDR: 92%; CK: 95%; p=0.83 At 5 y, 2D-EBRT: 77%; HDR ½ fr: 95.5%; HDR 3 fr: 82.4%; p=0.0194

DMFS7DFS At 3 y DFS, PDR: 86%; CK: 92%; p=0.15 At 5 y DFS, 2D-EBRT: 71.6%; HDR ½ fr: 92.4%; HDR 3 fr: 77%; p=0.0039

LC PDR: 94%; CK: 97%; 2D-EBRT: HDR ½ fr: HDR 3 fr: p=0.0064
At 3 y, p=0.33 At 5 y, 73.7%; 93.9%; 79.5%;

Boost treatment PDR: 22 Gy/8 fr; CK: 16.5 Gy/3 fr HDR: 5 – 16.5 Gy/1-3 fr; 2D-EBRT: 3.6 Gy
Table 5. Summary of head-and-neck cancer studies

n pts PDR: 148; CK: 102 HDR: 133; 2D-EBRT: 50

Study Retr Retr

Period 2000 – 2012 1979 – 1991

Authors Al-Mamgani et al. 26 Budrukkar et al. 29

Volume 3 Issue 3 (2025) 21 doi: 10.36922/ARNM025160017